• Health for Life Capital II™ fund and portfolio companies reported 2021 to have been a remarkable year
• 2022 continues to see significant investment in the microbiome, with record Series B fundraise by Microbiotica
• Health for Life Capital II™ fund closed at €250m, well above target
• Portfolio companies raised over €420m in total in 2021, MaaT Pharma listed on Euronext
Paris, France – Seventure Partners (Seventure), one of Europe’s leaders in financing innovation and a world leader in life science microbiome investment, and its portfolio companies have had an exceptional year in 2021. With the closing of Health for Life Capital II™ fund raising well above target and the recent record-breaking £50m fund raising from Microbiotica, 2022 is expected to be another significant year for the microbiome sector.
Seventure’s Health for Life Capital II™ fund closed last year at €250 million, which significantly exceeded the initial target size. This is Seventure’s second successful fund with its core investment focus on “beyond the pill”, encompassing areas such as the microbiome, personalized nutrition, foodtech, related digital/connected health, as well as wellbeing.
Health for Life Capital II™ was launched in March 2019, and comprises investments in eleven trailblazing companies, such as Axial Biotherapeutics, Abalos, BCD Bioscience, Citryll, Cytoki, Dermala, Ervaccine, Federation Bio, Galecto, Iome Bio, and Polaris. These portfolio companies are all active in microbiome-related disciplines, developing drugs or nutritional solutions, building on the connections of the microbiome to immune function, skin, CNS diseases, fibrosis and immuno-oncology, and more.
The pioneer Health for Life Capital™ fund, initiated in 2014, was the first ever fund with primary focus on the microbiome. Its final close was also well above its target, at €160M. It invested in 20 innovative companies in the microbiome field, including now renowned companies like Enterome, MaaT Pharma, TargEDys , Ysopia, BiomX, DayTwo, Eligo Bioscience, LiMM Therapeutics, Microbiotica, Myco Technology, Siolta, Vedanta Biosciences, and more..
Both Health for Life Capital™ funds attracted strategic investments from prestigious organisations, including Danone, Novartis, Bel, Lesaffre, Tereos, Tornier, Unigrains, additional corporations, as well as financial institutions, family offices and entrepreneurs.
“The microbiome sector has come a long way since our first fund was launched in 2014, and today it covers so much more than a decade ago,” commented Isabelle de Cremoux, CEO and Managing Partner, Seventure Partners, who led Health for Life Capital II™ fundraising. “The significant oversubscription of our second fund is proof that the “beyond-the-pill” sector has great potential as well as financial value for investors. We are delighted to see that there is a steadily increasing number of innovative companies in this area, as well as growing interest on the investment side. We are also delighted to see that our portfolio companies are doing exceptionally well and continue to thrive, preparing significant collaborations, partnerships and exits to be announced in the near future.”
Health for Life Capital™ Portfolio News
Portfolio companies of the Health for Life CapitalTM funds raised a total of USD 460m / €420m in 2021, ranging from seed to Series D financing rounds.
2022 started with promising news for the microbiome sector, with Microbiotica recently closing a £50M (USD 67m) Series B financing round, the largest living organism microbiome-related financing in Europe to date. This successful round of financing provides further evidence that the field of microbiome is and will continue to see growth and development.
One of the highlights of 2021 for this sector was the IPO of Maat Pharma on Euronext.
Among other fundraises, CytoKi Pharma raised $45m in a Series A financing round, while Foodsmart announced a Series C funding of over $25m to accelerate its commercial development in personalised nutrition. Dopavision closed a €12m Series A round to fund the clinical development of MyopiaX for childhood myopia, while Vedanta closed a $68m Series D round. Axial Biotherapeutics closed $37.3m Series C to advance it pipeline in neurological disease and disorders, particularlyautism. In addition, Abalos Therapeutics completed a Series A extension reaching a total of €43m, while ErVaccine received $3m seed funding.
2021 also saw some promising partnerships formed with Eligo Bioscience SA entering into a research and option agreement with GSK, and Galecto entered into a clinical trial supply agreement with Roche.
Numerous clinical trials also progressed: Enterome saw the first dosing of a patient in its Phase 1/2 trial for indolent non-Hodgkin B-cell lymphoma, while Ysopia Bioscience completed its Causality Phase 1 trial in evaluating their oral biotherapy based on a selected live bacterial strain of Christensenella minuta, targeting obesity and associated metabolic abnormalities. Citryll also dosed the first healthy volunteer in their Phase 1 clinical trial evaluating their therapeutic antibody targeting Neutrophil Extracellular Trap (NET), developed for autoimmune and chronic inflammatory diseases and other indications. In addition, Axial Therapeutics dosed its first subjects in a Phase 2b trial for their gut-targeted molecular therapeutics for Irritability in Autism Spectrum Disorder and published promising results for its Phase 1b/2a study in Nature Medicine.
Health for Life Capital II™ portfolio companies have also been recognised with awards, with BCD Bioscience being one of two winners at the Wonderful Company $1 million Wonderful Innovation Challenge. Dermala was recently selected for Cosmopolitan’s Holy Grail Acne Awards as well as receiving Grand Prize at the inaugural Colgate Connect Challenge awards.
About Seventure Partners
Seventure Partners is a long-term equity investor who actively supports innovative companies aiming at generating positive impacts on Humankind, Society, Sustainability and the Planet.
With €900m net commitments under management as of the end of 2021, Seventure is a leading venture capital firm in Europe investing since 1997 in innovative businesses with high growth potential in two main fields: Life sciences (health & digital health, nutrition, foodtech, blue economy, aquaculture, animal & agriculture, sport & wellness …) across Europe, Israel, Asia and North America and Digital technologies in Europe.
Investments can range between €500k and €10m per round, or up to €20m per company, from early to late stage, growth, pre-IPO and IPO.
With Health for Life Capital™ funds (€160m and €250m) and its co-investments funds, Seventure is worldwide leader in Microbiome investments with portfolio companies such as Enterome, Eligo Bioscience, LiMM Therapeutics, MaaT Pharma, TargEDys, Ysopia Biosciences in France, as well as A-Mansia Biotech, BiomX, Cambrooke, Daytwo, Microbiotica, Siolta Therapeutics, Vedanta Biosciences, Axial Therapeutics, Citryll, Federation Bio, Galecto, Abalos, Cytoki etc. Seventure is also one of the first investors in the Foodtech sector, with investments in companies including Myco technology, BCD and Foodsmart (formerly Zipongo) in the US, Polaris and Laviefoods in France.
The Health for Life Capital™ funds attracted strategic investments from prestigious organizations including Danone, Novartis, two US-based global food ingredient providers (to be disclosed), Lesaffre, Tornier, Tereos, Unigrains and Bel, as well as financial institutions, family offices and entrepreneurs.
The Digital Opportunities Fund™ launched in 2016 and its successor in 2021 are institutional venture capital funds supporting fintech, retailtech and other innovative digital solutions.
The AVF fund, launched in 2018, supports companies in feed, animal nutrition and animal health with Adisseo as strategic partner.
The Sport & Performance Capital institutional fund, launched in 2019, supports companies in the sports and wellness sector.
The BlueForwardFund™, launched in 2022, invests in the blue economy (carbon capture, hydrogen, blue bio-based products including bioplastics, to improve use of marine resources, micro-organisms and algae, waste and circular blue economy, sustainable aquaculture, ocean diversity, blue economy digitalization and more).
For more information please contact: firstname.lastname@example.org